AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,830.00
-150.00 (-1.88%)
Jun 5, 2025, 3:30 PM KST

AptaBio Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
-27,991-29,378-12,062-10,565
Depreciation & Amortization
532.1531.35539.11484.62
Loss (Gain) From Sale of Investments
-20.11583.55244.292,494
Loss (Gain) on Equity Investments
385.79583.54.19-
Stock-Based Compensation
232.79234.34186.65123.6
Other Operating Activities
12,17712,478-2,458631.31
Change in Accounts Receivable
-487.56-893.71--
Change in Inventory
-151.66-224.87--
Change in Accounts Payable
115.031.87--
Change in Other Net Operating Assets
-1,0423,924-549.77-1.91
Operating Cash Flow
-16,250-12,160-14,095-6,833
Capital Expenditures
-277.03-240.16-1,345-1,041
Sale (Purchase) of Intangibles
---46.6-10.36
Investment in Securities
9,60313,521-9,0065,332
Other Investing Activities
-55.62-55.6260.1527.66
Investing Cash Flow
9,27012,854-12,7371,743
Long-Term Debt Issued
--38,900-
Long-Term Debt Repaid
--134.01-127.85-87.95
Net Debt Issued (Repaid)
-135.88-134.0138,772-87.95
Issuance of Common Stock
---589.2
Other Financing Activities
-32.7-33.3-19.2-5.24
Financing Cash Flow
-168.58-167.3149,854496.01
Foreign Exchange Rate Adjustments
-14.18-1.195.0716.76
Miscellaneous Cash Flow Adjustments
-0-0-00
Net Cash Flow
-7,162525.3323,027-4,577
Free Cash Flow
-16,527-12,400-15,440-7,874
Free Cash Flow Margin
-532.01%-368.94%-4767.39%-16284.04%
Free Cash Flow Per Share
-685.88-526.67-692.42-353.27
Cash Interest Paid
9.610.211.474.49
Cash Income Tax Paid
63.276.1848.45-34.01
Levered Free Cash Flow
-5,784-1,924-13,398-
Unlevered Free Cash Flow
-3,922201.3-12,659-
Change in Net Working Capital
-8,237-12,6231,429-
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.